Vaccine-Preventable Diseases

Matthew Washam, MD, MPH
Assistant Professor
Department of Pediatrics
Section of Infectious Diseases
Nationwide Children's Hospital

Disclosure Statement

 I have no conflicts of interest to disclose relevant to today's presentation

Vaccine-Preventable Diseases


- Anthrax
- Cholera
- Diphtheria
- Hepatitis A
- Hepatitis B
- H. influenzae type B
- HPV
- Seasonal influenza


- Japanese encephalitis
- Meningococus
- Mumps
- Pertussis
- Pneumococcus
- Polio
- Rabies
- Rotavirus
- Rubella


- Shingles
- Smallpox
- Tetanus
- Typhoid fever
- Varicella
- Yellow fever


Life Before Vaccines


- Diphtheria and smallpox outbreaks
- Summer infantile paralysis epidemics
- Near universal infection with measles and pertussis during childhood
- Congential rubella syndrome
- Invasive Haemophilus influenzae type B disease
- The list goes on...





















Re-emergence of Vaccine Preventable Diseases

- Contributing Factors:
 - Decreased vaccination rates
 - Endemic transmission
 - Increased international travel
 - Waning vaccine-mediated immunity

Outline

- Notable VPDs in the clinic setting:
 - Measles
 - Mumps
 - Hepatitis A
 - Influenza addressed in separate webcast
- Common vaccine questions from patients







Measles Clinical Features

- Incubation Period: 8-12 days (range: 7-21 days)
- Symptoms arise as two distinct phases:
 - Prodrome
 - 2-4 days prior to rash onset
 - Fever & "the 3 C's"
 - Koplik spots
 - Rash
 - · Cephalocaudal progression
 - Confluence
 - Fading with desquamation
- Infectious 4 days prior to 4 days after rash onset







Measles Complications

- Acute Otitis Media
- Diarrhea
- Febrile Seizures
- Pneumonia
- Encephalitis
- Post-infectious encephalomyelitis
- Subacute sclerosing panencephalitis



Measles Diagnosis

- RT-PCR
 - Nasopharyngeal or throat swab specimen
 - Highest sensitivity during first 3 days of rash
- Serology
 - · IgM
 - Acute specimens may have false negative results
 - False positives may occur with other viral infections
 - IgG
 - Usually positive by 1-2 weeks after rash onset

Measles Treatment and Prophylaxis

- Treatment
 - Supportive
 - Vitamin A for hospitalized children
- Post-Exposure Prophylaxis
 - MMR Vaccine within 72 hours
 - Immunoglobulin within 6 days
 - Intramuscular immune globulin
 - -Infants
 - Intravenous immune globulin
 - -Immunocompromised children and adults
 - Pregnant women without evidence of immunity

Measles Prevention

- Prevention
 - 2 dose MMR series in childhood
 - Other indications:
 - Students at post-high school educational institutions
 - Adults born during or after 1957
 - Prior to international travel
 - Healthcare personnel



Mumps


- Highly contagious Spread via respiratory droplets
- Endemic transmission ongoing in US





Mumps Clinical Features

- Incubation period 16-18 days (range: 12-25 days)
- Non-specific prodromal symptoms
- Tender unilateral or bilateral parotitis
 - Symptoms peak in 1-3 days
 - Resolve over 1 week
- Clinical presentation may vary
 - Asymptomatic
 - Non-specific respiratory symptoms
- Infectious 2 days before to 5 days after parotitis onset







Ear Protrusion &

Obscuring of the angle of the jaw common




Source: CDC

Mumps Complications

- Occur less commonly in vaccinated patients
- Complications are more common in adults
- Orchitis
- Oophoritis
- Mastitis



Mumps Complications MUMPS More than just swollen glands MUMPS CAN BE DANGEROUS Before there was a vaccine, numps was one of the most common causes of: DEAFNESS and MENINGITIS (infection of the brain and spinal cord covering) in childhood. Mumps can also lead to ENCEPHALITIS (swelling of the brain) in some children. Source: CDC



Mumps Testing Considerations

- Previously vaccinated patients:
 - Obtain PCR specimens within 1-3 days after onset
 - May have transient or undetectable IgM
 - IgG during acute phase usually very high

Mumps Treatment and Prophylaxis

- Treatment
 - Supportive
- Post-exposure prophylaxis
 - None

Mumps Prevention

- Prevention
 - 2 dose MMR series in childhood
 - Other indications:
 - Students at post-high school educational institutions
 - Adults born during or after 1957
 - Prior to international travel
 - Healthcare personnel
 - 3rd dose for high risk groups during outbreak



Source: CDC

Hepatitis A


- Transmission routes:
 - Fecal-oral
 - Contaminated food or water
- Risk factors:
 - Contact with infected person
 - International travel
 - Men who have sex with men
 - Users of injection and non-injection drugs
 - Persons with clotting factor disorders
 - Working with NHP


Hepatitis A Clinical Features

- Incubation period: 28 days (range: 15-50 days)
- Most children < 6 years asymptomatic
- · Older children and adults:
 - Fever
 - Fatigue
 - Abdominal pain
 - Nausea and vomiting
 - Diarrhea
 - Jaundice

Hepatitis A Clinical Features

- Symptoms resolve in < 2 months
- Prolonged or relapsing disease may occur
- Does not cause chronic infection
- Infectious from 2 weeks before to 1 week after jaundice onset





Hepatitis A Treatment and Prophylaxis

- Treatment
 - Supportive
- Post-Exposure Prophylaxis within 14 days of exposure
 - Hepatitis A vaccine
 - Healthy persons aged ≥ 12 months
 - Immune globulin & hepatitis A vaccine
 - Immunocompromised persons aged ≥ 12 months
 - · Chronic liver disease
 - Healthy persons aged > 40
 - Immune globulin alone
 - Infants < 12 months

WASH YOUR HANDS after using the toilet Wash with the following the toilet Wash with the following the following


Hepatitis A vaccination is recommended for:

- · All children at age 1 year
- Travelers to countries where hepatitis A is common
- Family and caregivers of adoptees from countries where hepatitis A is common
- Men who have sexual encounters with other men
- People who use or inject drugs
- People with chronic or long-term liver disease, including hepatitis B or hepatitis C
- · People with clotting factor disorders
- People with direct contact with others who have hepatitis A
- People experiencing homelessness

Source: CDC

Hepatitis A Prevention

- Other patient populations to vaccinate:
 - Persons at increased risk of complications
 - Congenital or acquired immunodeficiency
 - HIV infection
 - Hemodialysis
 - Transplant recipients
 - · latrogenic immune suppression
 - Occupational risks
 - Nonhuman primates
 - Working with HAV in research laboratory



Common Questions and Concerns

- Too many vaccines
 - Contrast vaccine antigens with every day exposures
- Vaccines make me sick
 - Educate on immune response
- Vaccines contain aluminum or other metals
 - No known safety risks with amount in vaccines
 - · Ingested in food and water daily
- Delayed vaccine schedule
 - No data that delayed schedule is more safe
 - Any time delay places at risk

Common Questions and Concerns

- Delay for mild illness
 - Mild febrile illnesses are not contraindications
- VPDs don't exist anymore
 - Educate on international and US outbreaks
 - "One plane ride away"



Source: CDC

Summary

- One of greatest public health achievements
- VPDs still exist in US and internationally
- Maintain high level of clinical suspicion
- Encourage families and patients to vaccinate